Holdings
FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC
Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings
Novo Holdings Spearheads $100M Series C Financing for SiteOne Therapeutics to Develop Non-Opioid Pain Therapies
Novo Holdings, SiteOne Therapeutics, Non-opioid pain treatments, Series C financing, Ion channel modulators, Peripheral nervous system (PNS) pain treatments, Chronic pain management, Opioid epidemic
Novo Holdings to Finalize $16.5B Acquisition of Catalent Following Regulatory Clearance
Novo Holdings, Catalent, Acquisition, Regulatory Clearance, Life Sciences, Pharmaceutical Development
European Commission Approves Novo Holdings’ $16.5B Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, Pharmaceutical Industry
Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, EU Approval, Pharmaceutical Services
Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline
Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate
Catalent Misses Revenue Estimates Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Novo Holdings, Acquisition, Revenue Estimates, Pharmaceutical Market, Competition, FTC, Antitrust
Catalent Falls Short of Q1 Revenue Projections Amid Growing Opposition to Novo Holdings’ $16.5 Billion Acquisition
Catalent, Q1 Revenue, Novo Holdings, Acquisition, Pharmaceutical Industry, Contract Manufacturing
EU Regulators Schedule December 6 Decision on Novo Holdings’ Acquisition of Catalent
EU regulators, Novo Holdings, Catalent, acquisition, antitrust review, December 6 deadline
Roche CEO Urges Antitrust Regulators to Block Novo Holdings’ Acquisition of Catalent
Novo Holdings, Catalent, Roche, Antitrust Regulators, Pharmaceutical Industry, Mergers and Acquisitions